Back to All Events

JLabs: Investor Spotlight: Debiopharm

On November 23rd, Tanja Dowe, CEO, and Tom Gibbs, Director, of Debiopharm Innovation Fund S.A will be in attendance to give an overview presentation about their company's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.

Debiopharm Innovation Fund is the strategic investment fund of the Debiopharm Group, a global pharmaceutical group. Debiopharm invests in innovative companies in smart data (pilot or early commercial stage), therapeutics (discovery or early development), and diagnostics (development stage). They focus their efforts on technologies related to oncology and infectious disease, Debiopharm’s therapeutic areas of interest. They participate in average rounds of $20-40M, with some early stage rounds in the $1-3M range. Debiopharm seeks a minority position, actively participates in boards, and is willing to lead rounds.

If you are applying to pitch, let us know. The OBIO team can help you be seen by investors and provide you with strategic insights.
 

Information & Registration

Earlier Event: November 8
Marketing Drugs in the U.S. - Webinar
Later Event: November 27
OBIO 2017 APM